The rise of CAR-T and other gene therapies, newly identified oncology targets and next-generation sequencing will shape the pipeline for 2018.
With the first CAR T-cell therapy approved, this new form of immunotherapy has a bright future. Yet drug companies also need to respond to worrisome side effects, such as severe cytokine release syndrome.
Josh Baxt, a science and health care writer, suggests on PharmExec.com:
Besides CAR-T, multiple sclerosis (MS) therapeutics offer high hopes, with Celgene announcing positive results for its trial of ozanimod. Epilepsy is also getting much attention. The sales of GW Pharmaceuticals’ cannabinoid product Epidiolex are predicted to reach $1 billion by 2022."Despite setbacks, CAR-T is rolling forward. Novartis’ Kymriah was approved in August to treat ALL. The price tag is steep at $475,000, but pretty much in line with a bone marrow transplant. In October, the FDA approved Kite’s Yescarta for NHL."
More gene and cell-based therapies in oncology, ophthalmology, hemophilia and other inherited blood disease are poised to lift off.
Meanwhile, the Alzheimer’s pipeline keeps coming up short. High-profile failures for amyloid plaque have led to skepticism on the amyloid hypothesis.